Kasabach-Merritt syndrome and interferon alpha: still a controversial issue * Authors' reply

Biban, Paolo

doi:10.1136/adc.88.7.645-b

Cited by 8 publications

(2 citation statements)

References 1 publication

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Bevacizumab's use is currently being explored in a variety of vascular malformations and vascular tumors [85][86][87]. Bevacizumab has been successfully used in combination with steroids and radiation [88,89].…”

Section: Anti-angiogenic Agentsmentioning

confidence: 99%

Clinical Review: Management of Adult Kasabach-Merritt Syndrome Associated with Hemangiomas

Master¹,

Kallam²,

Eo³

et al. 2017

J Blood Disord Transfus

View full text Add to dashboard Cite

Kasabach-Merritt syndrome (KMS) consists of a clinical trial of capillary hemangioma, thrombocytopenia and disseminated intravascular coagulation. KMS occurs most commonly in the pediatric population, and its occurrence in adults is rare. Specific guidelines or randomized clinical trials guiding clinical management of KMS in adult patients are lacking. This manuscript provides a comprehensive review of KMS and discusses recent advances in the medical management of KMS. We also propose a systematic therapeutic approach which would serve as a guide in the management of adult patients with KMS caused by hemangiomas.

show abstract

Section: Anti-angiogenic Agentsmentioning

confidence: 99%

Clinical Review: Management of Adult Kasabach-Merritt Syndrome Associated with Hemangiomas

Master¹,

Kallam²,

Eo³

et al. 2017

J Blood Disord Transfus

View full text Add to dashboard Cite

show abstract

“…Considering its tumor characteristics, various treatments have been reported for KMS, including glucocorticoids, interferon, cytotoxic drugs, radiotherapy, and arterial embolization. [4][5][6][7][8][9][10][11][12] Glucocorticoids (prednisone 2-3 mg/kg/day) are commonly used, and megadose methylprednisolone (30 mg/kg/day) may be administered for 3 consecutive days before administering prednisone in severe cases. 13 In the current case, we designed a combined regimen comprising prednisone, vincristine, and thalidomide.…”

Section: Discussionmentioning

confidence: 99%

Successful treatment of an adult with Kasabach-Merritt syndrome using thalidomide, vincristine, and prednisone

et al. 2019

View full text Add to dashboard Cite

Objective Kasabach-Merritt syndrome is a rare disease that mainly occurs in infants and adolescents. It usually manifests as disseminated intravascular coagulation and severe bleeding, and is associated with high mortality. However, its low incidence and clinical rarity in adults mean that there is currently no well-verified treatment regimen for this disease. We report on an effective novel therapeutic regimen in a patient with Kasabach-Merritt syndrome. Methods A woman with Kasabach-Merritt syndrome presented with a recurrent subcutaneous mass and disseminated intravascular coagulation, and was treated with prednisone, vincristine and thalidomide. Results This treatment regimen successfully resolved the patient’s symptoms, with tumor regression. The patient remained disease-free after 6 years of follow-up. Conclusions Prednisone combined with vincristine and thalidomide may be an effective treatment for Kasabach-Merritt syndrome, but further studies are needed to verify the use of this regimen.

show abstract